Marshall Fordyce - 13 Nov 2024 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
13 Nov 2024
Net transactions value
-$1,427,323
Form type
4
Filing time
15 Nov 2024, 16:05:16 UTC
Previous filing
25 Oct 2024
Next filing
27 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $35,393 +12,218 +14% $2.90 98,160 13 Nov 2024 Direct F1
transaction VERA Class A Common Stock Sale $605,314 -12,218 -12% $49.54 85,942 13 Nov 2024 Direct F2, F3
transaction VERA Class A Common Stock Options Exercise $9,580 +3,307 +3.8% $2.90 89,249 13 Nov 2024 Direct
transaction VERA Class A Common Stock Sale $166,281 -3,307 -3.7% $50.28 85,942 13 Nov 2024 Direct F2, F4
transaction VERA Class A Common Stock Options Exercise $290 +100 +0.12% $2.90 86,042 13 Nov 2024 Direct
transaction VERA Class A Common Stock Sale $5,120 -100 -0.12% $51.20 85,942 13 Nov 2024 Direct F2
transaction VERA Class A Common Stock Options Exercise $4,533 +1,565 +1.8% $2.90 87,507 13 Nov 2024 Direct
transaction VERA Class A Common Stock Sale $77,603 -1,565 -1.8% $49.59 85,942 13 Nov 2024 Direct F2, F5
transaction VERA Class A Common Stock Options Exercise $898 +310 +0.36% $2.90 86,252 13 Nov 2024 Direct
transaction VERA Class A Common Stock Sale $15,609 -310 -0.36% $50.35 85,942 13 Nov 2024 Direct F2, F6
transaction VERA Class A Common Stock Options Exercise $5,432 +1,875 +2.2% $2.90 87,817 13 Nov 2024 Direct
transaction VERA Class A Common Stock Sale $92,951 -1,875 -2.1% $49.57 85,942 13 Nov 2024 Direct F2, F7
transaction VERA Class A Common Stock Options Exercise $5,432 +1,875 +2.2% $2.90 87,817 13 Nov 2024 Direct
transaction VERA Class A Common Stock Sale $92,848 -1,875 -2.1% $49.52 85,942 13 Nov 2024 Direct F2, F7
transaction VERA Class A Common Stock Options Exercise $5,432 +1,875 +2.2% $2.90 87,817 13 Nov 2024 Direct
transaction VERA Class A Common Stock Sale $92,811 -1,875 -2.1% $49.50 85,942 13 Nov 2024 Direct F2, F7
transaction VERA Class A Common Stock Options Exercise $21,726 +7,500 +8.7% $2.90 93,442 13 Nov 2024 Direct
transaction VERA Class A Common Stock Sale $367,500 -7,500 -8% $49.00 85,942 13 Nov 2024 Direct F2
holding VERA Class A Common Stock 222,030 13 Nov 2024 By GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -15,625 -2% $0.000000 753,587 13 Nov 2024 Class A Common Stock 15,625 $2.90 Direct F8
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -1,875 -0.25% $0.000000 751,712 13 Nov 2024 Class A Common Stock 1,875 $2.90 Direct F8
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -1,875 -0.25% $0.000000 749,837 13 Nov 2024 Class A Common Stock 1,875 $2.90 Direct F8
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -1,875 -0.25% $0.000000 747,962 13 Nov 2024 Class A Common Stock 1,875 $2.90 Direct F8
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -1,875 -0.25% $0.000000 746,087 13 Nov 2024 Class A Common Stock 1,875 $2.90 Direct F8
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -7,500 -1% $0.000000 738,587 13 Nov 2024 Class A Common Stock 7,500 $2.90 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Excludes 222,030 shares previously owned directly, which on November 7, 2024, were contributed to a grantor retained annuity trust, in which the Reporting Person is the sole grantee and annuitant.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
F3 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.02 to $50.01, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.02 to $50.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.05 to $50.03, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F6 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.13 to $50.78, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F7 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F8 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.